AB125. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality
نویسندگان
چکیده
© Translational Andrology and Urology. All rights reserved. Transl Androl Urol, 2015;4(S1) www.amepc.org/tau undergoing this procedure remains controversial, however. We evaluated a new method involving cystoscopic sleeve resection of the distal ureter using a 2-μm continuous wave laser before LNU. Patients and methods: LNU was performed in 38 patients at our hospital between January 2008 and January 2012. The distal end of the ureter was managed by using a 2-μm continuous wave laser to evaporate and excise the ureteral orifice and bladder cuff. A standard technique was applied to keep the ureter intact. The ureter was dissected to the entrance of the bladder, and the distal ureter was easily detached from the bladder. Results: The distal ureter was excised completely in all cases using this new technique. The average operative time was 2.4 hours, and the average blood loss was 69.4 mL. At 1 year after surgery, the cause-specific survival rate of the patients was 100%, the bladder recurrence-free rate was 89%, and the extravesical recurrence-free rate was 100%. Conclusions: For managing the distal ureter during LNU, the new technique described proved to be a simple, safe, and minimally invasive method.
منابع مشابه
From Papanicolaou to papillomaviruses: evolving challenges in cervical cancer screening in the era of human papillomavirus vaccination.
References 1. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection. The effect of study arm on prostate cancer treatment in the large screening trial ERSPC. Impact of androgen deprivation therapy on cardiovascu...
متن کاملCardiovascular risk associated with androgen deprivation therapy.
Prostate cancer is the second leading cause of cancer-related death among men in the United States.[1] Androgen deprivation therapy (ADT) is a common treatment for prostate cancer. ADT includes gonadotropin-releasing hormone (GnRH) agonists (leuprolide, goserelin, triptorelin), bilateral orchiectomy, and anti-androgen receptor blockers such as flutamide and bicalutamide. Several studies have no...
متن کاملAndrogen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.
BACKGROUND The use of androgen deprivation therapy (ADT) in the treatment of men with prostate cancer has risen sharply. Although cardiovascular disease is the most common reason for death among men with prostate cancer who do not die of the disease itself, data regarding the effect of ADT on cardiovascular morbidity and mortality in men with prostate cancer are limited. In the current study, t...
متن کاملThe modern role of androgen deprivation therapy in the management of localised and locally advanced prostate cancer
INTRODUCTION Approximately 50% of men diagnosed with prostate cancer will be exposed to androgen deprivation therapy (ADT) at some stage. The role of ADT in the management of metastatic disease has long been recognised, and its place in the management of localised and locally advanced disease has become clearer in the past few years. Nevertheless, concerns remain that some men might not benefit...
متن کاملThe Role of PDE-5 Inhibitors in Prostate Cancer
Prostate cancer currently stands as the most frequently diagnosed solid tumor in men, and remains one of the leading causes of cancer mortality in men in the Western world, accounting for an estimated 32,050 deaths in the United States in 2010 (Jemal et al., 2010). With the wellknown use of serum prostate-specific antigen (PSA) as a screening tool, men are being diagnosed with earlier stage dis...
متن کامل